Results 81 to 90 of about 3,081 (193)

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis

While pirtobrutinib is established in Bruton tyrosine kinase inhibitor (BTKi)-refractory disease, its role in BTKi-naïve relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) remains unclear because of the absence of direct comparative trials ...
Allsup, David, Molica, Stefano, Giannarelli, Diana   +2 more
core   +1 more source

BTK‐Inhibition Enhances TLR‐7‐Mediated Interferon‐Alpha Production in pDCs by Blocking the Inhibitory BDCA‐2 Pathway [PDF]

In pDCs, BTK-inhibition (BTKi) blocks the IFN-α production via TLR-9, but not via TLR-7. Upon TLR-7 stimulation, BTKi enhances the production of IFN-α by blocking the inhibitory BDCA-2 pathway.
Meinl, Edgar, Ceglarek, Laura, Gerhards, Ramona, Peters, Anneli, Boldrini, Vinicius, Wichmann, Christian   +5 more
core   +1 more source

498 Bruton’s tyrosine kinase (BTK) inhibitors impede platelet aggregation but not adhesion to collagen.

Journal of Clinical and Translational Science
OBJECTIVES/GOALS: The research objectives of this project are to elucidate the effects of Bruton’s tyrosine kinase inhibitors (BTKi) of varying target specificity on platelet function with regard to platelet aggregation, adhesion, spreading, and ...
Thomas Kartika, Lorena Buitrago, Jihong Li, Barry S. Coller   +3 more
doaj   +1 more source

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma

Biomarker Research
Inhibitors of Bruton’s tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 are paradigm-shifting advances in treating patients with aggressive mantle cell lymphoma (MCL).
Vivian Jiang, William Lee, Tianci Zhang, Alexa Jordan, Fangfang Yan, Qingsong Cai, Joseph McIntosh, Jovanny Vargas, Yang Liu, Michael Wang   +9 more
doaj   +1 more source

Whole Transcriptome Analysis of Aedes albopictus Mosquito Head and Thorax Post-Chikungunya Virus Infection

Pathogens, 2019
Chikungunya virus (CHIKV) is transmitted by Aedes mosquitoes and causes prolonged arthralgia in patients. After crossing the mosquito midgut barrier, the virus disseminates to tissues including the head and salivary glands.
Ravi kiran Vedururu, Matthew J. Neave, Vinod Sundaramoorthy, Diane Green, Jennifer A. Harper, Paul R. Gorry, Jean-Bernard Duchemin, Prasad N. Paradkar   +7 more
doaj   +1 more source

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study

Marginal zone lymphoma (MZL) is a group of indolent B-cell malignancies that have a natural history that follows a remitting and relapsing course. For systemic disease, available first-line therapies include anti-CD20 antibody as monotherapy with or in ...
Hoffmann, Marc S, Brown, Jennifer R, Alencar, Alvaro J, Fakhri, Bita, Scarfò, Lydia, Balbas, Minna, Bian, Yuanyuan, Patel, Manish R, Munir, Talha, Nasta, Sunita D, Patel, Krish, Zelenetz, Andrew D, Jagadeesh, Deepa, Shah, Nirav N, Cheah, Chan Y, Rhodes, Joanna M, Eyre, Toby A, Zinzani, Pier Luigi Luigi, Tessoulin, Benoit, Cohen, Jonathon B, Abada, Paolo B, Lewis, David John, Tsai, Donald E, Woyach, Jennifer A, Ma, Shuo, Lech-Maranda, Ewa, Coombs, Catherine C, Maddocks, Kami J, Vose, Julie M, Li, Mei, Ujjani, Chaitra S   +30 more
core   +1 more source

P112 | REAL-WORLD OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BTK INHIBITORS WHO DISCONTINUED TREATMENT FOR REASONS OTHER THAN DISEASE PROGRESSION: EXPERIENCE FROM PIEDMONT CENTERS

Haematologica
Background: The advent of Bruton's tyrosine kinase inhibitors (BTKi) has revolutionized the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). BTKi are administered continuously until progression or unacceptable toxicity.
M. Bullo, D. Cilloni, C. Vitale, F. Perutelli, G. Catania, M. Nicolosi, M. Canepari, D. Gottardi   +7 more
doaj  

BTK Inhibitor Synergizes With CD19‐Targeted Chimeric Antigen Receptor‐T Cells in Patients With Relapsed or Refractory B‐Cell Lymphoma: An Open‐Label Pragmatic Clinical Trial

Cancer Medicine
Background CD19‐targeted chimeric antigen receptor‐T cell (CART19) therapy is clinically effective in patients with relapsed or refractory B‐cell lymphoma (BCL), but treatment failure and recurrence need to be overcome.
Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Zhuolin Wu, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Heng Mei, Yu Hu   +13 more
doaj   +1 more source

Abstracts of 14th International Symposium on Hodgkin Lymphoma

HemaSphere, Volume 10, Issue S2, October 2026.
wiley   +1 more source

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study

: Relapsed/refractory (R/R) follicular lymphoma (FL) is a chronic disease often requiring multiple lines of therapy. Covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy has resulted in variable response rates, yet patients invariably experience ...
Jonathon B. Cohen, Sunita D. Nasta, Manish R. Patel, Krish Patel, Daisuke Ennishi, Catherine C. Coombs, Andrew D. Zelenetz, Kensuke Kojima, Yuanyuan Bian, Yoshiaki Ogawa, Michael Wang, Kaname Miyashita, Bita Fakhri, Minna Balbas, Anastasios Stathis, Nirav N. Shah, Minal A. Barve, Daigo Hashimoto, Pier Luigi Zinzani, Fangfang Sun, Talha Munir, Shuo Ma, Kami J. Maddocks, Benoit Tessoulin, Chan Y. Cheah, Ewa Lech-Maranda, Paolo Abada, Julie M. Vose, Bryone Kuss, Donald E. Tsai   +29 more
core   +1 more source